Asston Pharmaceuticals Ltd vs Eris Lifesciences Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 18, 2026

Key Highlights

The Latest Trading Price of Asston Pharmaceuticals Ltd is ₹ 73 as of 18 May 15:30 . The P/E Ratio of Asston Pharmaceuticals Ltd changed from 0 on March 2021 to 0 on March 2025 . This represents a CAGR of 0.0% over 5 yearsThe P/E Ratio of ERIS Lifesciences Ltd changed from 23.1 on March 2021 to 54.8 on March 2025 . This represents a CAGR of 18.86% over 5 years The Market Cap of Asston Pharmaceuticals Ltd changed from ₹ 0 crore on March 2021 to ₹ 0 crore on March 2025 . This represents a CAGR of 0.0% over 5 yearsThe Market Cap of ERIS Lifesciences Ltd changed from ₹ 8207 crore on March 2021 to ₹ 19287 crore on March 2025 . This represents a CAGR of 18.64% over 5 years The revenue of Asston Pharmaceuticals Ltd for the Dec '25 is ₹ 0 crore as compare to the Sep '25 revenue of ₹ 0 crore. This represent the decline of 0% The revenue of ERIS Lifesciences Ltd for the Dec '25 is ₹ 807.59 crore as compare to the Sep '25 revenue of ₹ 795.5 crore. This represent the growth of 1.52% The ebitda of Asston Pharmaceuticals Ltd for the Dec '25 is ₹ 0 crore as compare to the Sep '25 ebitda of ₹ 0 crore. This represent the decline of 0% The ebitda of ERIS Lifesciences Ltd for the Dec '25 is ₹ 264.51 crore as compare to the Sep '25 ebitda of ₹ 291.3 crore. This represent the decline of -9.2% The net profit of Asston Pharmaceuticals Ltd changed from ₹ 0 crore to ₹ 0 crore over 7 quarters. This represents a CAGR of 0.0% The net profit of ERIS Lifesciences Ltd changed from ₹ 89.55 crore to ₹ 108.83 crore over 7 quarters. This represents a CAGR of 11.79% The Dividend Payout of Asston Pharmaceuticals Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 yearsThe Dividend Payout of ERIS Lifesciences Ltd changed from 21.3 % on March 2021 to 129.35 % on March 2025 . This represents a CAGR of 43.44% over 5 years .

About Asston Pharmaceuticals Ltd

Asston Pharmaceuticals Limited was incorporated on 16th April 2019 as 'Asston Pharmaceutical Pvt.
Limited' to contract produce pharmaceutical products for export market.
Later on 1st April 2024, Company acquired Ferron Lifecare Private Limited, specializing into nutraceuticals business and produced nutraceutical products at their Ambarnath facility.
Ferron Lifecare Private Limited, incorporated on 30th January 2020.
Finally, 'Asston Pharmaceuticals Private Limited' was converted into a Public Limited Company in the name of 'Asston Pharmaceuticals Limited' on 29th August 2024 and received FDA approval for its Ambarnath facility on 2nd December 2024 to produce pharmaceutical products. Presently, Company is involved in the business of manufacturing and marketing of Tablets, Capsules, Oral Liquid, External Preparations (Ointment, Cream, Gel and Lotion) and Oral Powder (Sachet, Dry Syrup) etc.

About ERIS Lifesciences Ltd

Eris Lifesciences Limited was incorporated on January 25, 2007.
Subsequently, the name of the company was changed to 'Eris Lifesciences Private Limited' on February 9, 2007.
Further, the Company was converted into a Public Limited cCompany and the name was changed to 'Eris Lifesciences Limited' on February 2, 2017.
The Company has a manufacturing plant in Guwahati, Assam and is presently engaged in manufacturing and marketing of pharmaceutical products.
It has presence in high growth chronic, sub chronic and acute therapeutic areas that require high intervention of specialist and super specialist doctors. The company develops, manufactures and commercializes branded pharmaceutical products in selected therapeutic areas within chronic and acute categories of the Indian Pharmaceutical Market (IPM), such as: cardiovascular; anti-diabetics; vitamins; gastroenterology; and anti-infective.

FAQs for the comparison of Asston Pharmaceuticals Ltd and ERIS Lifesciences Ltd

Which company has a larger market capitalization, Asston Pharmaceuticals Ltd or ERIS Lifesciences Ltd?

Market cap of Asston Pharmaceuticals Ltd is 65 Cr while Market cap of ERIS Lifesciences Ltd is 19,038 Cr

What are the key factors driving the stock performance of Asston Pharmaceuticals Ltd and ERIS Lifesciences Ltd?

The stock performance of Asston Pharmaceuticals Ltd and ERIS Lifesciences Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Asston Pharmaceuticals Ltd and ERIS Lifesciences Ltd?

As of May 18, 2026, the Asston Pharmaceuticals Ltd stock price is INR ₹76.75. On the other hand, ERIS Lifesciences Ltd stock price is INR ₹1373.95.

How do dividend payouts of Asston Pharmaceuticals Ltd and ERIS Lifesciences Ltd compare?

To compare the dividend payouts of Asston Pharmaceuticals Ltd and ERIS Lifesciences Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.